EFSs allow first-in-human use of a novel device based on less nonclinical evidence than a traditional IDE, with allowances for iterative device modifications during the study. FDA's 2013 guidance on early feasibility studies describes the program, which enrolls a small number of subjects, often around 10, at an early design stage. FDA allows a lighter nonclinical package when justified, and design changes during the study can often be made with notice or quick review. The program aims to bring early device innovation back to the US.

Why it matters

Strategically valuable for breakthrough cardiovascular, neuro, and surgical devices needing early clinical signal to inform design freeze.

Common pitfalls

•A common pitfall is misunderstanding the reduced non-clinical evidence requirements, which are still substantial and must justify the proposed human use.
•Another mistake is failing to adequately plan for iterative device modifications, leading to delays in regulatory approvals.
•Companies often underestimate the importance of strong clinical protocol design and robust data collection in EFSs.
•Inadequate consideration of patient safety measures during the iterative design process can lead to serious compliance issues.

Sources

FDA EFS Guidance · FDA
ISO 14155 Standard Page · ISO
FDA - Clinical Trials and Human Subject Protection · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.